Introduction
============

In spite of improvements in surveillance and clinical treatment strategies, the overall survival (OS) of hepatocellular carcinoma (HCC) patients is unsatisfactory due to the high incidence of tumor recurrence and metastasis even after hepatectomy and lack of effective adjuvant therapy \[[@b1-crt-2015-302],[@b2-crt-2015-302]\]. Identification of reliable biomarkers that can be used in prediction of tumor recurrence or prognosis of HCC patients ensures more effective clinical management after curative hepatectomy \[[@b3-crt-2015-302]\].

Cell division cycle and apoptosis regulator 1 (CCAR1) was originally identified as a peri-nuclear phospho-protein reguired for apoptosis signaling by chemotherapy drugs adriamycin and etoposide independent of the p53 status of the human breast cancer cells \[[@b4-crt-2015-302]\]. Human *CCAR1* gene is located on chromosome 10q21-10q22. CCAR1 plays a dynamic role in regulation of cell growth and apoptosis by serving as a cofactor of steroid/thyroid nuclear receptors, β-catenin, and p53 in a variety of cell types including different cancer cells \[[@b5-crt-2015-302],[@b6-crt-2015-302]\]. Kim et al. \[[@b7-crt-2015-302]\] reported that CCAR1 promoted growth of MCF-7 human breast cancer cells in response to estradiol treatment. A recent study showed that CCAR1 was required for growth of prostate cancer cells in part by functioning as a coactivator of androgen receptor transcription \[[@b8-crt-2015-302]\]. Another study reported that CCAR1 was a binding partner of β-catenin and mediated anchorage independent growth of colon cancer cells \[[@b9-crt-2015-302]\]. However, whether CCAR1 protein is overexpressed in HCC and the prognostic significance of CCAR1 protein expression in HCC have not been reported.

In 167 HCC patients with long-term follow-up, CCAR1 protein expression was examined by immunohistochemistry to determine whether this protein can serve as a prognostic predictor.

Materials and Methods
=====================

1. Study subjects
-----------------

HCC tissues from 167 patients who underwent curative hepatectomy from July 2000 to May 2006 at Samsung Medical Center, Seoul, Korea were analyzed. Curative resection was defined as complete resection of all tumor nodules with clear microscopic resection margins and no residual tumors, as indicated by a computed tomography scan 1 month after surgery. All tumor tissues were histologically confirmed. None of the patients received preoperative or postoperative chemotherapy. This study was approved by the Institutional Review Board of Samsung Medical Center. Tumor stages were classified according to both the American Joint Committee on Cancer (AJCC) staging system \[[@b10-crt-2015-302]\] and Barcelona Clinic Liver Cancer (BCLC) staging classification \[[@b11-crt-2015-302]\]. Intrahepatic metastasis and multicentric occurrence were defined according to the previously reported criteria \[[@b12-crt-2015-302]\]. Using 2 years as the cut off, tumor recurrence was classified as either early recurrence or late recurrence \[[@b13-crt-2015-302]\]. Tumor tissue microarrays were produced as described previously \[[@b14-crt-2015-302]\]. Two 2-mm cores were taken from paraffin blocks of each specimen.

All patients were followed up every 3 months after surgery and serum α-fetoprotein levels were assessed and three phase dynamic computed tomography scans or magnetic resonance imaging were performed. The median follow-up period was 119.1 months (range, 24.0 to 151.4 months) for survivors. Recurrence-free survival (RFS) was defined from the date of surgery until the date of tumor recurrence, metastasis, or last follow-up. OS was defined from the date of surgery until the date of death or last follow-up. HCC-related death was defined as: (1) tumor occupying more than 80% of the liver, (2) portal venous tumor thrombus proximal to the second bifurcation, (3) obstructive jaundice due to the tumor, (4) distant metastases, or (5) variceal hemorrhage with portal venous tumor thrombus proximal to the first bifurcation \[[@b15-crt-2015-302]\]. Hepatic failure was defined as the inability of the liver to perform its normal synthetic and metabolic function as part of normal physiology \[[@b16-crt-2015-302]\].

2. Immunohistochemical analysis
-------------------------------

Immunohistochemistry was performed as previously described \[[@b14-crt-2015-302]\]. Epitope retrieval was performed with 0.01 mol/L citrate buffer at pH 6.0 for 30 minutes in a pressure cooker. The sections were incubated with rabbit polyclonal antibody to CCAR1 (HPA007856, 1:100, Sigma-Aldrich Inc., St. Louis, MO) for 60 minutes at room temperature. To validate the concordance between tissue microarrays and whole tumor sections, CCAR1 expression was also detected for 40 corresponding whole tumor sections randomly chosen from the 167 cases. In negative controls, pre-immune rabbit serum was used to substitute for the primary antibody. Positive controls (human normal kidney) showed nuclear CCAR1 expression in epithelial cells of convoluted tubules.

Immunoreactivity was evaluated independently by two blinded pathologists (C.-K.P. and S.Y.H.). Nearly homogeneous nuclear immunostaining with moderate staining intensity was observed. To determine CCAR1 protein expression, the percentage of tumor cells with positive staining was scored from 0% to 100% and each sample was rated from 0 to 4 (0, \< 5%; 1, 5%-25%; 2, 26%-50%; 3, 51%-75%; and 4, \> 75%). Duplicate tissue cores for each tumor showed high levels of homogeneity for the proportion of tumor cells with positive staining.

3. Statistical analysis
-----------------------

Statistical analyses were performed using SPSS ver. 18 (SPSS Inc., Chicago, IL). The chi-square test or Fisher exact test was used to examine possible correlations between CCAR1 expression and clinicopathologic factors. A logistic regression analysis was used to predict tumor recurrence. Survival curves were constructed using the Kaplan-Meier method, and differences in survival were evaluated using a log-rank test. Univariate and multivariate analyses of survival were performed using the Cox proportional hazards regression model. Factors with prognostic significance in the univariate analysis were included in the subsequent multivariate analysis. A p-value of \< 0.05 was considered to indicate statistical significance.

Results
=======

1. Clinicopathologic patient characteristics
--------------------------------------------

The study included 139 men and 28 women with an average age of 52.5 years (range, 17 to 76 years). The adjacent non-tumor liver had liver cirrhosis in 88 cases (52.7%) ([Table 1](#t1-crt-2015-302){ref-type="table"}). Tumor recurrence was detected in 122 patients (73.1%), early recurrence in 98 patients (58.7%), and late recurrence in 24 patients (14.4%). Seventy-two patients (43.1%) died of HCC. Of the 86 deaths, 14 were due to non-HCC causes. Eight of these 14 deaths were due to hepatic failure, five were due to non-hepatic causes, and one was due to unknown cause.

2. CCAR1 protein expression in HCC
----------------------------------

In HCC, immunoreactivity for CCAR1 was observed in the nucleus of tumor cells with moderate staining intensity. No immunoreactivity was found in normal hepatocytes. In normal livers, weak CCAR1 immunoreactivity was observed in the nucleus of bile duct epithelial cells, Kupffer cells, and lymphocytes. CCAR1 immunoreactivity was graded as low (0%-50% stained tumor cells regardless of staining intensity) or high expression (\> 50% stained tumor cells). High CCAR1 immunoreactivity was observed in 149 of the 167 HCC cases (89.2%) ([Fig. 1](#f1-crt-2015-302){ref-type="fig"}). High CCAR1 expression showed significant correlation with microvascular invasion (p=0.002), intrahepatic metastasis (p=0.015), and higher AJCC T stage (p=0.017). High CCAR1 expression showed significant correlation with early recurrence (p=0.001), but not with late recurrence (p=0.121) ([Table 1](#t1-crt-2015-302){ref-type="table"}).

3. Prediction of early recurrence in HCC
----------------------------------------

In univariate analysis, early recurrence showed significant correlation with microvascular invasion (p \< 0.001), intrahepatic metastasis (p \< 0.001), higher AJCC T stage (p \< 0.001), higher BCLC stage (p=0.002), lower albumin level (p=0.049), viral etiology (p=0.001), and high CCAR1 expression (p=0.002). To avoid potential bias, because AJCC T stage and BCLC stage were associated with vascular invasion, multiple analyses with these variables were not performed. The significance of serum α-fetoprotein level was not evaluated because of missing data (n=161). In multivariate analysis, intrahepatic metastasis (p=0.010) and viral etiology (p=0.019) were independent predictors of early recurrence ([Table 2](#t2-crt-2015-302){ref-type="table"}).

4. Association between CCAR1 expression and prognosis of HCC patients
---------------------------------------------------------------------

The RFS and OS rates for 167 HCC patients were 35.7% and 71.7% at 3 years, 32.0% and 60.7% at 5 years, 27.1% and 51.1% at 7 years, and 26.0% and 46.6% at 9 years, respectively. In univariate analysis, larger tumor size, microvascular invasion, major portal vein invasion, intrahepatic metastasis, higher AJCC T stage, higher BCLC stage, and lower albumin level showed unfavorable effects on both RFS and OS. Higher α-fetoprotein level and viral etiology showed unfavorable effects on RFS. High CCAR1 expression showed unfavorable effects on both RFS and OS ([Table 3](#t3-crt-2015-302){ref-type="table"}).

The 5-year RFS rate of the high CCAR1 expression group was significantly lower than that of the low CCAR1 expression group (27.1% vs. 72.2%) (p=0.002) ([Fig. 2A](#f2-crt-2015-302){ref-type="fig"}). The mean RFS was 42.5 months for the high CCAR1 expression group and 100.9 months for the low CCAR1 expression group. In subgroup analysis, among patients with α-fetoprotein ≤ 20 ng/mL (n=54) and patients with AJCC T stage 1 (n=62), significant differences in RFS were observed between high CCAR1 expression groups (n=41 and n=50, respectively) and low CCAR1 expression groups (p=0.015 and p=0.004, respectively) ([Fig. 2B](#f2-crt-2015-302){ref-type="fig"} and [C](#f2-crt-2015-302){ref-type="fig"}). In further analysis, among patients with tumor size ≤ 5.0 cm (n=96), no significant difference in RFS was observed between high CCAR1 expression group (n=86) and low CCAR1 expression group (p=0.189) ([Fig. 2D](#f2-crt-2015-302){ref-type="fig"}).

The 5-year OS rate of the high CCAR1 expression group was significantly lower than that of the low CCAR1 expression group (58.0% vs. 83.3%) (p=0.015) ([Fig. 3A](#f3-crt-2015-302){ref-type="fig"}). The mean OS was 86.9 months for the high CCAR1 expression group and 126.1 months for the low CCAR1 expression group. In subgroup analysis, among patients with α-fetoprotein ≤ 20 ng/mL (n=54), significant difference in OS was observed between high CCAR1 expression group (n=41) and low CCAR1 expression group (p=0.046) ([Fig. 3B](#f3-crt-2015-302){ref-type="fig"}). In further analysis, among patients with AJCC T stage 1 (n=62), the high CCAR1 expression group (n=50) tended to show an unfavorable effect on OS (p=0.089) ([Fig. 3C](#f3-crt-2015-302){ref-type="fig"}). Among patients with tumor size ≤ 5.0 cm (n=96), no significant difference in OS was observed between high CCAR1 expression group (n=86) and low CCAR1 expression group (p=0.448) ([Fig. 3D](#f3-crt-2015-302){ref-type="fig"}).

In multivariate analysis, intrahepatic metastasis and lower albumin level were independent predictors of both shorter RFS and shorter OS. Viral etiology was an independent predictor of shorter RFS. High CCAR1 expression tended to be an independent predictor of shorter RFS (p=0.054), but not shorter OS (p=0.348). Patients with high CCAR1 expression were more likely to suffer from recurrence than those with low CCAR1 expression (hazard ratio, 2.184) ([Table 4](#t4-crt-2015-302){ref-type="table"}).

Discussion
==========

CCAR1 plays important roles in regulation of cancer cell growth in part by recruiting multiple mediators and confers optimal conformation for transcriptional functions of nuclear receptors \[[@b7-crt-2015-302]-[@b9-crt-2015-302]\]. Apoptosis induction by CCAR1 involves its binding with 14-3-3 protein and down-regulation of cell growth and cell cycle regulators c-Myc, topoisomerase IIα, cyclin B, and p21 Rac1 \[[@b4-crt-2015-302]\]. Diminished expression of CCAR1 in human breast cancers involved methylation-dependent gene silencing associated with hypermethylation of CCAR1 promoter \[[@b17-crt-2015-302]\]. CCAR1 functional mimetics (CFMs) are novel small molecule inhibitors of CCAR1 interaction with anaphase promoting complex/cyclosome \[[@b18-crt-2015-302]\]. CFMs promote apoptosis in a manner independent of p53. CFMs are potent inhibitors of a variety of cancer cells including drug (adriamycin or tamoxifen)--resistant breast cancer cells but not immortalized breast epithelial cells in part by activating apoptosis signaling and diminishing the levels of key cell cycle regulatory proteins \[[@b18-crt-2015-302],[@b19-crt-2015-302]\].

This study demonstrates, for the first time, that high CCAR1 protein expression in HCC might be a marker of shorter RFS after curative hepatectomy. High CCAR1 expression showed correlation with microvascular invasion, intrahepatic metastasis, and higher AJCC T stage, suggesting the involvement of CCAR1 in the progression of HCC.

In the current study, tumor recurrence was detected in 35 of 54 patients (64.8%) with normal serum α-fetoprotein levels and in 36 of 62 patients (58.1%) with AJCC T stage 1. Within these patient populations, high CCAR1 expression groups showed unfavorable effects on RFS. Serum α-fetoprotein is an important predictor of HCC recurrence after surgery \[[@b20-crt-2015-302]\]. Identification of subpopulations with poor prognosis for early stage HCC patients is critical to the optimization of personalized treatment. CCAR1 protein expression may be helpful in prediction of recurrence risk in patients with normal serum α-fetoprotein levels and early stage HCC after curative hepatectomy.

In addition, CCAR1 could be a promising therapeutic target for HCC. A nanolipid formulation of CFM-4 showed superior bioavailability and inhibited growth of xenografted triple-negative breast cancer and non-small cell lung cancer in nude mice, when administered orally \[[@b19-crt-2015-302]\]. The absence of CCAR1 protein expression in the normal liver enhances the potential of CCAR1 as a treatment target in HCC. Current treatment options for HCCs are limited, thus discovery and development of molecules based on CCAR1 signaling could yield novel tools for treatment of HCCs.

Conclusion
==========

For the first time, the current study demonstrated that CCAR1 protein could be a potential biomarker predicting RFS in HCC patients after curative hepatectomy. In addition, CCAR1 had prognostic values in HCC patients with normal serum α-fetoprotein levels or early stage HCC. Patients with high CCAR1 expression are considered candidates for adjuvant treatment after surgical resection. Further study is needed to determine the underlying molecular mechanism of CCAR1 in the development and progression of HCC.
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###### 

Correlation between CCAR1 expression and the clinicopathologic features in 167 hepatocellular carcinomas

  Variable                                                               No.   CCAR1 high expression   p-value
  ---------------------------------------------------------------------- ----- ----------------------- ---------
  **Age (yr)**                                                                                         
   ≤ 55                                                                  94    86 (91.5)               0.284
   \> 55                                                                 73    63 (86.3)               
  **Sex**                                                                                              
   Female                                                                28    26 (92.9)               0.741
   Male                                                                  139   123 (88.5)              
  **Tumor size (cm)**                                                                                  
   ≤ 5.0                                                                 96    86 (89.6)               0.861
   \> 5.0                                                                71    63 (88.7)               
  **Edmondson grade**                                                                                  
   I                                                                     13    11 (84.6)               0.608
   II                                                                    116   101 (87.1)              
   III                                                                   38    37 (97.4)               
  **Microvascular invasion**                                                                           
   (--)                                                                  65    52 (80.0)               0.002
   (+)                                                                   102   97 (95.1)               
  **Major portal vein invasion**                                                                       
   (--)                                                                  158   140 (88.6)              0.599
   (+)                                                                   9     9 (100)                 
  **Intrahepatic metastasis**                                                                          
   (--)                                                                  116   99 (85.3)               0.015
   (+)                                                                   51    50 (98.0)               
  **Multicentric occurrence**                                                                          
   (--)                                                                  162   145 (89.5)              0.439
   (+)                                                                   5     4 (80.0)                
  **AJCC T stage**                                                                                     
   1                                                                     62    50 (80.6)               0.017
   2                                                                     68    62 (91.2)               
   3                                                                     35    35 (100)                
   4                                                                     2     2 (100)                 
  **BCLC stage**                                                                                       
   0-A                                                                   81    73 (90.1)               0.608
   B                                                                     76    66 (86.8)               
   C                                                                     10    10 (100)                
  **Albumin level (g/dL)**                                                                             
   \> 3.5                                                                142   124 (87.3)              0.078
   ≤ 3.5                                                                 25    25 (100)                
  **AFP level (ng/mL)**^[a)](#tfn1-crt-2015-302){ref-type="table-fn"}^                                 
   ≤ 200                                                                 92    79 (85.9)               0.170
   \> 200                                                                69    64 (92.8)               
  **Etiology**                                                                                         
   Non-viral                                                             22    18 (81.8)               0.540
   HBV                                                                   130   117 (90.0)              
   HCV                                                                   15    14 (93.3)               
  **Liver cirrhosis**                                                                                  
   (--)                                                                  79    70 (88.6)               0.808
   (+)                                                                   88    79 (89.8)               
  **Early recurrence (≤ 2 yr)**                                                                        
   (--)^[b)](#tfn2-crt-2015-302){ref-type="table-fn"}^                   45    34 (75.6)               0.001
   (+)                                                                   98    93 (94.9)               
  **Late recurrence (\> 2 yr)**                                                                        
   (--)^[b)](#tfn2-crt-2015-302){ref-type="table-fn"}^                   45    34 (75.6)               0.121
   (+)                                                                   24    22 (91.7)               

Values are presented as number (%). CCAR1, cell division cycle and apoptosis regulator 1; AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus.

Partial data were not available,

No early or late recurrence.

###### 

Univariate and multivariate logistic regression models for predicting early tumor recurrence in 143 hepatocellular carcinomas

  Variable                                                                                  Univariate model   Multivariate model                                                
  ----------------------------------------------------------------------------------------- ------------------ ----------------------- ---------- ------- ---------------------- -------
  Age (\> 55 yr vs. ≤ 55 yr)                                                                --0.285            0.752 (0.370-1.528)     0.431      \-      \-                     \-
  Sex (male vs. female)                                                                     --0.588            0.556 (0.192-1.605)     0.278      \-      \-                     \-
  Tumor size (\> 5.0 cm vs. ≤ 5.0 cm)                                                       0.734              2.083 (0.998-4.347)     0.050      \-      \-                     \-
  Edmondson grade (III vs. I+II)                                                            0.565              1.759 (0.727-4.255)     0.210      \-      \-                     \-
  Microvascular invasion (yes vs. no)                                                       1.645              5.182 (2.418-11.104)    \< 0.001   0.865   2.376 (0.943-5.987)    0.067
  Major portal vein invasion (yes vs. no)                                                   1.364              3.911 (0.474-32.256)    0.205      \-      \-                     \-
  Intrahepatic metastasis (yes vs. no)                                                      2.557              12.902 (3.747-44.430)   \< 0.001   1.787   5.971 (1.533-23.249)   0.010
  Multicentric occurrence (yes vs. no)                                                      0.329              1.389 (0.141-13.738)    0.778      \-      \-                     \-
  AJCC T stage (2+3+4 vs. 1)                                                                1.675              5.337 (2.474-11.514)    \< 0.001   \-      \-                     \-
  BCLC stage (B+C vs. A+0)                                                                  1.182              3.262 (1.561-6.818)     0.002      \-      \-                     \-
  Albumin level (≤ 3.5 g/dL vs. \> 3.5 g/dL)                                                1.278              3.590 (1.008-12.784)    0.049      1.294   3.646 (0.862-15.421)   0.079
  AFP level^[a)](#tfn3-crt-2015-302){ref-type="table-fn"}^ (\> 200 ng/mL vs. ≤ 200 ng/mL)   0.000              1.000 (0.997-1.002)     0.949      \-      \-                     \-
  Etiology (viral vs. non-viral)                                                            1.664              5.281 (1.937-14.403)    0.001      1.371   3.938 (1.258-12.323)   0.019
  Liver cirrhosis (yes vs. no)                                                              0.663              1.940 (0.943-3.993)     0.072      \-      \-                     \-
  CCAR1 expression (high vs. low)                                                           1.795              6.018 (1.948-18.587)    0.002      0.945   2.573 (0.716-9.247)    0.147

OR, odds ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; CCAR1, cell division cycle and apoptosis regulator 1.

Partial data were not available, and statistics were based on the available data.

###### 

Univariate analyses of recurrence-free survival and overall survival in 167 hepatocellular carcinomas

  Variable                                                                                  Recurrence-free survival   Overall survival                         
  ----------------------------------------------------------------------------------------- -------------------------- ------------------ --------------------- ----------
  Age (\> 55 yr vs. ≤ 55 yr)                                                                0.851 (0.593-1.219)        0.378              1.005 (0.657-1.535)   0.983
  Sex (male vs. female)                                                                     0.840 (0.533-1.322)        0.451              1.297 (0.719-2.341)   0.388
  Tumor size (\> 5.0 cm vs. ≤ 5.0 cm)                                                       1.653 (1.156-2.363)        0.006              2.143 (1.402-3.277)   \< 0.001
  Edmondson grade (III vs. I+II)                                                            1.384 (0.915-2.092)        0.124              1.542 (0.956-2.487)   0.076
  Microvascular invasion (yes vs. no)                                                       2.470 (1.677-3.638)        \< 0.001           3.324 (2.010-5.497)   \< 0.001
  Major portal vein invasion (yes vs. no)                                                   2.572 (1.250-5.291)        0.010              4.121 (1.968-8.629)   \< 0.001
  Intrahepatic metastasis (yes vs. no)                                                      3.680 (2.516-5.381)        \< 0.001           4.995 (3.235-7.711)   \< 0.001
  Multicentric occurrence (yes vs. no)                                                      1.309 (0.481-3.560)        0.598              1.157 (0.366-3.664)   0.804
  AJCC T stage (2+3+4 vs. 1)                                                                2.531 (1.707-3.752)        \< 0.001           3.579 (2.123-6.034)   \< 0.001
  BCLC stage (B+C vs. 0+A)                                                                  2.084 (1.452-2.992)        \< 0.001           2.937 (1.874-4.603)   \< 0.001
  Albumin level (≤ 3.5 g/dL vs. \> 3.5 g/dL)                                                1.870 (1.175-2.976)        0.008              2.612 (1.576-4.328)   \< 0.001
  AFP level^[a)](#tfn4-crt-2015-302){ref-type="table-fn"}^ (\> 200 ng/mL vs. ≤ 200 ng/mL)   1.493 (1.038-2.147)        0.031              1.291 (0.840-1.985)   0.244
  Etiology (viral vs. non-viral)                                                            2.680 (1.357-5.292)        0.005              1.576 (0.789-3.145)   0.197
  Liver cirrhosis (yes vs. no)                                                              1.293 (0.902-1.853)        0.162              0.924 (0.605-1.410)   0.713
  CCAR1 expression (high vs. low)                                                           3.192 (1.483-6.872)        0.003              3.250 (1.191-8.870)   0.021

HR, hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; CCAR1, cell division cycle and apoptosis regulator 1.

Partial data were not available, and statistics were based on the available data.

###### 

Multivariate analyses of recurrence-free survival and overall survival in 167 hepatocellular carcinomas

  Variable                                     Recurrence-free survival   Overall survival                         
  -------------------------------------------- -------------------------- ------------------ --------------------- ----------
  Tumor size (\> 5.0 cm vs. ≤ 5.0 cm)          1.170 (0.770-1.777)        0.463              1.131 (0.697-1.836)   0.617
  Microvascular invasion (yes vs. no)          1.538 (0.945-2.501)        0.083              1.784 (0.943-3.375)   0.075
  Major portal vein invasion (yes vs. no)      0.787 (0.361-1.718)        0.548              1.262 (0.579-2.753)   0.558
  Intrahepatic metastasis (yes vs. no)         2.355 (1.461-3.794)        \< 0.001           3.349 (1.948-5.756)   \< 0.001
  Albumin level (≤ 3.5 g/dL vs. \> 3.5 g/dL)   1.666 (1.032-2.690)        0.037              2.765 (1.625-4.706)   \< 0.001
  Etiology (viral vs. non-viral)               2.148 (1.071-4.308)        0.031              \-                    \-
  CCAR1 expression (high vs. low)              2.184 (0.986-4.833)        0.054              1.646 (0.581-4.668)   0.348

HR, hazard ratio; CI, confidence interval; CCAR1, cell division cycle and apoptosis regulator 1.
